173 related articles for article (PubMed ID: 36965095)
1. Evaluation of diagnostic efficacy of NRP-1/CD304 in hematological diseases.
Liu YJ; Li XH; Song YL; Zhou YC; Cai RZ; Chi PD
Cancer Med; 2023 May; 12(10):11284-11292. PubMed ID: 36965095
[TBL] [Abstract][Full Text] [Related]
2. NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia.
Meyerson HJ; Blidaru G; Edinger A; Osei E; Schweitzer K; Fu P; Ho L
Am J Clin Pathol; 2012 Jan; 137(1):39-50. PubMed ID: 22180477
[TBL] [Abstract][Full Text] [Related]
3. Neuropilin-1/CD304 Expression by Flow Cytometry in Pediatric Precursor B-Acute Lymphoblastic Leukemia: A Minimal Residual Disease and Potential Prognostic Marker.
Abaza HM; Alfeky MAA; Eissa DS; Abdel Fattah MF; Annaka LM; Ebeid FS
J Pediatr Hematol Oncol; 2018 Apr; 40(3):200-207. PubMed ID: 29200164
[TBL] [Abstract][Full Text] [Related]
4. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.
Sędek Ł; Theunissen P; Sobral da Costa E; van der Sluijs-Gelling A; Mejstrikova E; Gaipa G; Sonsala A; Twardoch M; Oliveira E; Novakova M; Buracchi C; van Dongen JJM; Orfao A; van der Velden VHJ; Szczepański T;
J Immunol Methods; 2019 Dec; 475():112429. PubMed ID: 29530508
[TBL] [Abstract][Full Text] [Related]
7. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
Solly F; Angelot F; Garand R; Ferrand C; Seillès E; Schillinger F; Decobecq A; Billot M; Larosa F; Plouvier E; Deconinck E; Legrand F; Saas P; Rohrlich PS; Garnache-Ottou F
Cytometry A; 2012 Jan; 81(1):17-24. PubMed ID: 22052678
[TBL] [Abstract][Full Text] [Related]
8. Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis.
Angelot-Delettre F; Biichle S; Ferrand C; Seilles E; Gaugler B; Harrivel V; Rosenthal-Allieri MA; Deconinck E; Saas P; Garnache-Ottou F
Cytometry A; 2012 Aug; 81(8):718-24. PubMed ID: 22674796
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
[TBL] [Abstract][Full Text] [Related]
10. Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation.
Hamadeh F; Awadallah A; Meyerson HJ; Beck RC
Cytometry B Clin Cytom; 2020 Jan; 98(1):43-51. PubMed ID: 30614203
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical evaluation of BCL-2 expression in acute myeloid leukemia, myeloid sarcoma, and blastic plasmacytoid dendritic cell neoplasm].
Saika W; Kawahara M; Tashiro H; Teramoto Y; Nagai S; Kumode M; Iwasa M; Asai A; Fujishiro A; Nishimura R; Minamiguchi H; Moritani S; Kito K; Andoh A
Rinsho Ketsueki; 2020; 61(12):1647-1653. PubMed ID: 33441515
[TBL] [Abstract][Full Text] [Related]
12. Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review.
Liao H; Yu J; Liu Y; Zhao S; Zhu H; Xu D; Jiang N; Zheng Q
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2911-2919. PubMed ID: 35933443
[TBL] [Abstract][Full Text] [Related]
13. Pattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignancies.
Chan DW; Liang R; Kwong YL
Hematol Oncol; 1996 Jun; 14(2):57-66. PubMed ID: 8876635
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions.
Cheng J; Klairmont MM; Choi JK
Pediatr Blood Cancer; 2019 Jan; 66(1):e27453. PubMed ID: 30255571
[TBL] [Abstract][Full Text] [Related]
16. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
Bras AE; de Haas V; van Stigt A; Jongen-Lavrencic M; Beverloo HB; Te Marvelde JG; Zwaan CM; van Dongen JJM; Leusen JHW; van der Velden VHJ
Cytometry B Clin Cytom; 2019 Mar; 96(2):134-142. PubMed ID: 30450744
[TBL] [Abstract][Full Text] [Related]
17. CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.
Testa U; Pelosi E; Castelli G
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547472
[TBL] [Abstract][Full Text] [Related]
18. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
Guolo F; Minetto P; Clavio M; Marcolin R; Miglino M; Passannante M; Caviglia F; Ballerini F; Tedone E; Kunkl A; Mangerini R; Contini P; Colombo N; Cagnetta A; Cea M; Carminati E; Pugliese G; Gobbi M; Lemoli RM
Leuk Lymphoma; 2020 Jul; 61(7):1695-1701. PubMed ID: 32186422
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.
Renosi F; Roggy A; Giguelay A; Soret L; Viailly PJ; Cheok M; Biichle S; Angelot-Delettre F; Asnafi V; Macintyre E; Geffroy S; Callanan M; Petrella T; Deconinck E; Daguindau E; Harrivel V; Bouyer S; Salaun V; Saussoy P; Feuillard J; Fuseau P; Saas P; Adotévi O; Jardin F; Ferrand C; Preudhomme C; Colinge J; Roumier C; Garnache-Ottou F
Blood Adv; 2021 Mar; 5(5):1540-1551. PubMed ID: 33687433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
